8-K: Seer Inc. Reports 37% Revenue Growth in Q1 2025, Reaffirms Full-Year Outlook

Seer, Inc. announced a 37% increase in revenue for the first quarter of 2025, driven by higher product and service sales, and reiterated its full-year revenue guidance.

Summary

• Seer, Inc. reported its financial results for the first quarter ended March 31, 2025.
• Revenue for the quarter was $4.2 million, a 37% increase compared to $3.1 million in the same period last year.
• Product revenue reached $2.9 million, including $5 thousand from related parties, driven by sales of Proteograph instruments and consumable kits.
• Service revenue amounted to $1.2 million, including $47 thousand from related parties, primarily from Seer Technology Access Center service projects.
• Gross profit was $2.1 million, with a gross margin of 49%.
• Operating expenses decreased by 14% to $22.8 million, mainly due to lower stock-based compensation and laboratory expenses.
• Net loss was $19.9 million, an improvement from the $20.7 million loss in the prior year period.
• The company ended the quarter with approximately $285 million in cash, cash equivalents, and investments.
• Seer reaffirmed its full-year 2025 revenue guidance of $17 million to $18 million, representing a 24% growth at the midpoint compared to 2024.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong revenue growth and reaffirmed guidance, but the net loss and macroeconomic headwinds temper the overall sentiment.

Positives

• Revenue increased by 37% year-over-year, indicating strong growth.
• The company secured a significant contract with a new customer.
• Operating expenses decreased by 14%, improving cost management.
• The company has a strong cash position of approximately $285 million.
• Gross margin was a healthy 49%.

Negatives

• The company reported a net loss of $19.9 million for the quarter.
• The company has related party revenue and expenses.

Risks

• The company acknowledges persistent macroeconomic headwinds impacting the life sciences industry.
• The company expects near-term volatility to persist until the broader macro environment stabilizes.

Future Outlook

Seer expects full-year 2025 revenue to be in the range of $17 million to $18 million, representing growth of 24% at the midpoint over full year 2024.

Management Comments

• Omid Farokhzad, Chair and CEO of Seer, stated that they are proud of their strong first quarter performance, especially given the macroeconomic headwinds.
• Management believes that the biological insights unlocked by their technology will have a meaningful impact on human health.

Industry Context

Seer operates in the life sciences industry, specifically in the proteomics space. The company's performance is affected by macroeconomic conditions impacting the broader life sciences sector. The company is commercializing a disruptive new platform for proteomics.

Comparison to Industry Standards

• It's difficult to provide a precise comparison without knowing the specific growth rates and financial metrics of Seer's direct competitors in the proteomics market.
• Companies like Quantum-Si, Bruker, and Danaher are involved in proteomics and related technologies, but their specific financial performance and product offerings may differ significantly from Seer's.
• The 49% gross margin is a good result compared to other life science companies.

Related Party Transactions

• Product revenue included $5 thousand of related party revenue.
• Service revenue included $47 thousand of related party revenue.

Stakeholder Impact

• Shareholders: The revenue growth and reaffirmed guidance are positive for shareholders, but the net loss may be a concern.
• Employees: The company's growth and strong cash position are positive for employees.
• Customers: The company's products and services are intended to benefit customers in the life sciences industry.
• The company's strong cash position is positive for suppliers and creditors.

Next Steps

• Seer will host a conference call to discuss the first quarter 2025 financial results.
• The company will continue to focus on driving adoption of the Proteograph Product Suite.
• Seer will continue to monitor the macroeconomic environment and its impact on the business.

Key Dates

Keywords

proteomics, financial results, revenue, Seer, Proteograph, life sciences, Q1 2025